27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
The "Drug Overview: Trelegy Ellipta" report has been added to ResearchAndMarkets.com's offering.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Trelegy Ellipta ([fluticasone furoate + vilanterol + umeclidinium bromide]; GlaxoSmithKline) is a fixed triple combination inhaled corticosteroid/long-acting beta 2 agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA) therapy. The product contains the same ICS/LABA components as Breo ([fluticasone furoate + vilanterol]; GlaxoSmithKline/Innoviva), plus a LAMA component, umeclidinium bromide.
GlaxoSmithKline received approval for Trelegy Ellipta in chronic obstructive pulmonary disease in Q3 2017, and is currently evaluating the drug in asthma patients whose symptoms are inadequately controlled by ICS/LABA therapies.
List of Figures
Figure 1: Trelegy Ellipta for asthma - SWOT analysis
Figure 2: Drug assessment summary of Trelegy Ellipta in asthma
Figure 3: Drug assessment summary of Trelegy Ellipta in asthma
Want Private Access to Benzinga Analyst?
Check out the latest strategies our team of experts are using every week so that you can always adapt to the market like the pros!—Get FULL Access to This Week's Webinar Here.
Figure 4: Trelegy Ellipta sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
List of Tables
Table 1: Trelegy Ellipta drug profile
Table 2: Trelegy Ellipta Phase III trials in asthma
Table 3: Trelegy Ellipta sales for asthma across the US, Japan, and five major EU markets, by country (NYSE:M), 2017-26
For more information about this report visit https://www.researchandmarkets.com/research/rrpz48/glaxosmithklines?w=4
View source version on businesswire.com: https://www.businesswire.com/news/home/20180511005636/en/
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.